7 results on '"Bouvaist H"'
Number of results to display per page
Search Results
2. Improved ventilatory efficiency to evidence haemodynamic improvement after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension.
- Author
-
Madoun S, Piliero N, Guillien A, Salvat M, Thony F, Finas M, Augier C, Bouvaist H, and Degano B
- Subjects
- Chronic Disease, Hemodynamics, Humans, Pulmonary Artery, Treatment Outcome, Angioplasty, Balloon, Hypertension, Pulmonary complications, Hypertension, Pulmonary therapy, Pulmonary Embolism complications, Pulmonary Embolism therapy
- Abstract
Competing Interests: Conflict of interest: The authors disclose no potential conflicts of interest.
- Published
- 2022
- Full Text
- View/download PDF
3. Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension.
- Author
-
Sitbon O, Cottin V, Canuet M, Clerson P, Gressin V, Perchenet L, Bertoletti L, Bouvaist H, Picard F, Prévot G, Bergot E, and Simonneau G
- Subjects
- Drug Therapy, Combination, Endothelin Receptor Antagonists, Humans, Pyrimidines, Sulfonamides, Tadalafil, Pulmonary Arterial Hypertension
- Abstract
Competing Interests: Conflict of interest: O. Sitbon reports personal fees from Actelion Pharmaceuticals France Ltd for steering committee work and non-financial editorial support from Actelion Pharmaceuticals Ltd, during the conduct of the study; grants, personal fees for advisory board work, consultancy, steering committee work and lectures, and non-financial editorial support from Actelion Pharmaceuticals Ltd and GlaxoSmithKline, grants and personal fees for advisory board work, consultancy and lectures from Bayer HealthCare and Merck, personal fees for consultancy and advisory board work from Arena Pharmaceuticals, personal fees for advisory board work from Gossamer Bio and Ferrer, outside the submitted work. Conflict of interest: V. Cottin reports non-financial editorial support from Actelion Pharmaceuticals Ltd, personal fees for steering committee work from Actelion Pharmaceuticals France Ltd, during the conduct of the study; personal fees for advisory board work and lectures, and non-financial travel support from Actelion Pharmaceuticals Ltd, grants, personal fees for consultancy and lectures, and non-financial travel support from Boehringer Ingelheim and Roche, personal fees for advisory board and data monitoring committee work from Bayer/MSD and Galapagos, personal fees for adjudication committee work from Gilead, personal fees for advisory board work and lectures from Novartis, personal fees for lectures from Sanofi, personal fees for data monitoring and steering committee work from Promedior, personal fees for data monitoring committee work from Celgene and Galecto, outside the submitted work. Conflict of interest: M. Canuet reports non-financial editorial support from Actelion Pharmaceuticals Ltd, personal fees for steering committee work from Actelion Pharmaceuticals France Ltd, during the conduct of the study; personal fees for consultancy from Actelion Pharmaceuticals Ltd, outside the submitted work. Conflict of interest: P. Clerson reports non-financial editorial support from Actelion Pharmaceuticals Ltd, during the conduct of the study. Conflict of interest: V. Gressin reports non-financial editorial support from Actelion Pharmaceuticals Ltd, was an employee of Actelion Pharmaceuticals France Ltd during the conduct of the study, has RSU in parent company Johnson and Johnson, and owns shares in Idorsia Pharmaceuticals Ltd. Conflict of interest: L. Perchenet reports non-financial editorial support from Actelion Pharmaceuticals Ltd, during the conduct of the study; and is an employee of Actelion Pharmaceuticals Ltd. Conflict of interest: L. Bertoletti reports non-financial editorial support from Actelion Pharmaceuticals Ltd, during the conduct of the study; non-financial support for travel and advisory board work from Actelion Pharmaceuticals Ltd, personal fees for advisory board work and non-financial support for travel from Bayer, non-financial support for travel from Pfizer, personal fees for advisory board work from Daichii-Sankyo, outside the submitted work. Conflict of interest: H. Bouvaist reports non-financial editorial support from Actelion Pharmaceuticals Ltd, during the conduct of the study. Conflict of interest: F. Picard reports non-financial editorial support from Actelion Pharmaceuticals Ltd, personal fees for steering committee work from Actelion Pharmaceuticals France Ltd, during the conduct of the study; personal fees and non-financial support from Novartis, outside the submitted work. Conflict of interest: G. Prévot reports non-financial editorial support from Actelion Pharmaceuticals Ltd, personal fees for steering committee work from Actelion Pharmaceuticals France Ltd, during the conduct of the study. Conflict of interest: E. Bergot reports non-financial editorial support from Actelion Pharmaceuticals Ltd, personal fees for steering committee work from Actelion Pharmaceuticals France Ltd, during the conduct of the study; personal fees for advisory board work and lectures from Chiesi Pharmaceuticals, Actelion Pharmaceuticals Ltd, Boehringer Ingelheim, Roche, Novartis and AstraZeneca, outside the submitted work. Conflict of interest: G. Simonneau reports non-financial editorial support from Actelion Pharmaceuticals Ltd, personal fees for steering committee work and non-financial travel/accommodation support from Actelion Pharmaceuticals France Ltd, during the conduct of the study; grants, personal fees for consultancy and lectures and non-financial travel/accommodation support from Actelion Pharmaceuticals Ltd, grants, personal fees for consultancy, steering committee work and lectures, and non-financial travel/accommodation support from Bayer Healthcare, personal fees for consultancy and lectures and non-financial travel/accommodation support from MSD and Acceleron, outside the submitted work.
- Published
- 2020
- Full Text
- View/download PDF
4. Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution.
- Author
-
Yanaka K, Guillien A, Soumagne T, Benet J, Piliero N, Picard F, Pison C, Sitbon O, Bouvaist H, and Degano B
- Subjects
- Humans, Acetamides adverse effects, Acetamides therapeutic use, Antihypertensive Agents therapeutic use, Epoprostenol therapeutic use, Pulmonary Arterial Hypertension drug therapy, Pyrazines therapeutic use
- Abstract
Competing Interests: Conflict of interest: K. Yanaka has nothing to disclose. Conflict of interest: A. Guillien has nothing to disclose. Conflict of interest: T. Soumagne has nothing to disclose. Conflict of interest: J. Benet has nothing to disclose. Conflict of interest: N. Piliero has nothing to disclose. Conflict of interest: F. Picard has nothing to disclose. Conflict of interest: C. Pison reports grants and personal fees from GlaxoSmithKline, personal fees from Novartis Pharma, Boehringer Ingelheim and AstraZeneca, outside the submitted work. Conflict of interest: O. Sitbon reports personal fees from Arena Pharmaceuticals, Acceleron Pharmaceuticals and Gossamer Bio, personal fees and non-financial support from Actelion Pharmaceuticals, grants and personal fees from Bayer HealthCare and Merck, non-financial support from GlaxoSmithKline, outside the submitted work. Conflict of interest: H. Bouvaist reports grants and non-financial support from GlaxoSmithKline and Bayer HealthCare, personal fees and non-financial support from Actelion Pharmaceuticals, outside the submitted work. Conflict of interest: B. Degano reports personal fees and non-financial support from Actelion Pharmaceuticals, non-financial support from Bayer HealthCare, grants, personal fees and non-financial support from Novartis Pharma, personal fees from Chiesi, GlaxoSmithKline and Menarini, outside the submitted work.
- Published
- 2020
- Full Text
- View/download PDF
5. "Rehab for all!" Is it too early in pulmonary arterial hypertension?
- Author
-
Bertoletti L, Bouvaist H, Tromeur C, Bezzeghoud S, Dauphin C, Enache I, Bourdin A, Seronde MF, Montani D, Turquier S, and Pison C
- Subjects
- Exercise, Familial Primary Pulmonary Hypertension, Humans, Hypertension, Pulmonary, Pulmonary Arterial Hypertension
- Abstract
Competing Interests: Conflict of interest: L. Bertoletti has nothing to disclose. Conflict of interest: H. Bouvaist reports grants and non-financial support from GSK and MSD, and personal fees and non-financial support from Actelion, outside the submitted work. Conflict of interest: C. Tromeur has nothing to disclose. Conflict of interest: S. Bezzeghoud has nothing to disclose. Conflict of interest: C. Dauphin has nothing to disclose. Conflict of interest: I. Enache has nothing to disclose. Conflict of interest: A. Bourdin reports grants, personal fees, non-financial support and other from AstraZeneca, GSK and Boehringer Ingelheim, personal fees and other from Chiesi, personal fees, non-financial support and other from Novartis, Actelion and Sanofi Regeneron, and other funding from United Therapeutics, Vertex, Galapagos, Biogen and BTG, outside the submitted work. Conflict of interest: M-F. Seronde has nothing to disclose. Conflict of interest: D. Montani reports grants and personal fees from Actelion and Bayer, and personal fees from GSK, MSD and Pfizer, outside the submitted work. Conflict of interest: S. Turquier has nothing to disclose. Conflict of interest: C. Pison has nothing to disclose.
- Published
- 2019
- Full Text
- View/download PDF
6. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.
- Author
-
Weatherald J, Chaumais MC, Savale L, Jaïs X, Seferian A, Canuet M, Bouvaist H, Magro P, Bergeron A, Guignabert C, Sitbon O, Simonneau G, Humbert M, and Montani D
- Subjects
- Adolescent, Adult, Aged, Female, Follow-Up Studies, France, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Registries, Retrospective Studies, Vascular Resistance, Young Adult, Dasatinib adverse effects, Hypertension, Pulmonary chemically induced, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Protein Kinase Inhibitors adverse effects
- Abstract
This study aimed to describe the long-term outcomes of pulmonary arterial hypertension (PAH) induced by dasatinib.21 incident, right heart catheterisation-confirmed cases of dasatinib-induced PAH were identified from the French Pulmonary Hypertension Registry. Clinical and haemodynamic variables were compared from baseline to last follow-up (median (range) 24 (1-81) months).Median age was 52 years and 15 patients were female (71%). 19 patients received dasatinib for chronic myelogenous leukaemia for a median (range) duration of 42 (8-74) months before PAH diagnosis. No bone morphogenic protein receptor-2 ( BMPR2 ) mutations were found in the 10 patients tested. Dasatinib was uniformly discontinued and 11 patients received PAH medications. Four patients died during follow-up. New York Heart Association functional class improved from 76% in class III/IV to 90% in class I/II (p<0.01). Median (range) 6-min walk distance improved from 306 (0-660) to 430 (165-635) m (p<0.01). Median (range) mean pulmonary arterial pressure improved from 45 (30-70) to 26 (17-50) mmHg (p<0.01) and pulmonary vascular resistance from 6.1 (3.2-27.3) to 2.6 (1.2-5.9) Wood units (p<0.01). Patients treated with PAH medications had worse baseline haemodynamics but similar long-term outcomes to untreated patients. PAH persisted in 37% of patients.Dasatinib-induced PAH frequently improves after discontinuation but persisted in over one-third of patients, therefore systematic follow-up is essential., Competing Interests: Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com, (Copyright ©ERS 2017.)
- Published
- 2017
- Full Text
- View/download PDF
7. Initial dual oral combination therapy in pulmonary arterial hypertension.
- Author
-
Sitbon O, Sattler C, Bertoletti L, Savale L, Cottin V, Jaïs X, De Groote P, Chaouat A, Chabannes C, Bergot E, Bouvaist H, Dauphin C, Bourdin A, Bauer F, Montani D, Humbert M, and Simonneau G
- Subjects
- Adult, Aged, Antihypertensive Agents administration & dosage, Bosentan, Diethylpropion, Drug Therapy, Combination, Female, Follow-Up Studies, Hemodynamics, Humans, Hypertension, Pulmonary genetics, Male, Middle Aged, Patient Safety, Phenylpropionates administration & dosage, Pyridazines administration & dosage, Retrospective Studies, Severity of Illness Index, Sildenafil Citrate administration & dosage, Sulfonamides administration & dosage, Tadalafil administration & dosage, Time Factors, Treatment Outcome, Familial Primary Pulmonary Hypertension drug therapy, Familial Primary Pulmonary Hypertension physiopathology, Hypertension, Pulmonary drug therapy, Hypertension, Pulmonary physiopathology
- Abstract
Treatment for pulmonary arterial hypertension (PAH) has been underpinned by single-agent therapy to which concomitant drugs are added sequentially when pre-defined treatment goals are not met.This retrospective analysis of real-world clinical data in 97 patients with newly diagnosed PAH (86% in New York Heart Association functional class III-IV) explored initial dual oral combination treatment with bosentan plus sildenafil (n=61), bosentan plus tadalafil (n=17), ambrisentan plus tadalafil (n=11) or ambrisentan plus sildenafil (n=8).All regimens were associated with significant improvements in functional class, exercise capacity, dyspnoea and haemodynamic indices after 4 months of therapy. Over a median follow-up period of 30 months, 75 (82%) patients were still alive, 53 (71%) of whom received only dual oral combination therapy. Overall survival rates were 97%, 94% and 83% at 1, 2 and 3 years, respectively, and 96%, 94% and 84%, respectively, for the patients with idiopathic PAH, heritable PAH and anorexigen-induced PAH. Expected survival rates calculated from the French equation for the latter were 86%, 75% and 66% at 1, 2 and 3 years, respectively.Initial combination of oral PAH-targeted medications may offer clinical benefits, especially in PAH patients with severe haemodynamic impairment., (Copyright ©ERS 2016.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.